Polydextrose Gummies Tested for Weight Control in Adults With Excess Weight
Compares polydextrose fiber gummies with placebo gummies in adults with obesity.
Plain-language title generated from the registry record
Registry title: Polydextrose Functional Gummies for Weight Management in Adults With Overweight or Obesity
Key facts
- Where
- Alcalá de Henares, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07758387, who can take part
Where in Spain
- Hospital Universitario Principe de AsturiasAlcalá de Henares, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nutris We Care About You S.L.
- Trial code
- NCT07758387
- Record updated
- 14 August 2026
- Original description
Overweight and obesity are common conditions that increase the risk of metabolic and cardiovascular diseases. Polydextrose is a type of dietary fiber that may help increase feelings of fullness by influencing natural hormones involved in appetite regulation. It may also improve postprandial glycemic responses and modulate the gut microbiota. However, evidence for its effectiveness in weight management remains limited.Read full original descriptionShow less
Randomized Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Functional Gummies With Polydextrose Versus Placebo for Weight Control in Adults With Overweight or Obesity
Overweight and obesity are common conditions that increase the risk of metabolic and cardiovascular diseases. Polydextrose is a type of dietary fiber that may help increase feelings of fullness by influencing natural hormones involved in appetite regulation. It may also improve postprandial glycemic responses and modulate the gut microbiota. However, evidence for its effectiveness in weight management remains limited.
The purpose of this study is to evaluate the efficacy and safety of functional gummies containing polydextrose compared with placebo for weight management in adults with overweight or obesity. Participants will be randomly assigned to receive either polydextrose or placebo gummies for 24 weeks, together with standardized dietary and physical activity recommendations.
The primary objective is to compare the percentage change in body weight over 24 weeks between participants receiving polydextrose gummies and those receiving placebo. The study will also evaluate appetite and satiety, body composition, waist circumference, metabolic parameters, quality of life, gastrointestinal symptoms, and the safety and tolerability of the study product.
The study hypothesis is that daily intake of polydextrose gummies for 24 weeks will lead to a greater reduction in body weight than placebo and may improve subjective feelings of appetite and satiety in adults with overweight or obesity.
Inclusion: Adults aged 18 to 70 years; Body mass index (BMI) between 25 and 39.9 kg/m² (overweight or obesity class I-II); Stable body weight (no change greater than 3%) in the 3 months before joining the study; Usually eat at least 2 meals per day; Able and willing to follow the study procedures for 24 weeks, attend all scheduled visits, and complete the required records; Willing and able to sign the informed consent form.
Exclusion: Currently taking or having taken in the last 3 months medicines that affect appetite or body weight (such as anorectic drugs, GLP-1 receptor agonists, chronic corticosteroids, antipsychotics, or fiber supplements); Uncontrolled thyroid disease [thyroid-stimulating hormone (TSH) outside the normal range] or recent changes in thyroid medication in the last 3 months; Significant gastrointestinal disease (such as severe irritable bowel syndrome, Crohn's disease, or ulcerative colitis); History of bariatric surgery; Advanced chronic kidney disease (stage IV-V); Current or recent eating disorder; Known allergy or intolerance to any ingredient of the study gummies; History of severe gastrointestinal problems with fermentable fibers; Type 2 diabetes with glycated hemoglobin (HbA1c) greater than 7%, type 1 diabetes, or type 2 diabetes treated with multiple daily insulin injections; Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors for diabetes, heart failure, or chronic kidney disease; Liver cirrhosis; Following a very low-calorie diet (less than 800 kcal/day); Alcohol dependence or heavy alcohol use that, in the investigator's opinion, could affect the study; Planning to start or recently started a specific weight-loss diet different from the one recommended by the study endocrinology service; Pregnancy or breastfeeding; Women of childbearing potential who are trying to become pregnant or plan to become pregnant during the study.